SHINE Technologies

We're thrilled that Wisconsin has been designated as a Biohealth Tech Hub. This is how you build a sustainable future - by investing in technology that solves real problems today. Because in the end, it's not just about the tech—it's about improving lives. Congrats Biohealth Tech Hub members! Wisconsin is where the future is being made!

Introducing Ilumira. Ilumira is the active pharmaceutical ingredient showing promise in the fight against various cancers, including neuroendocrine tumors and prostate cancer. Its targeted approach makes it a valuable tool for patients who have not responded well to other treatments. By delivering radiation directly to cancer cells, Ilumira offers new hope for patients with advanced or difficult-to-treat cancers, potentially improving outcomes and quality of life. Learn more about Ilumira by visiting this link https://hubs.li/Q02DK2ng0

Ilumira’s purity and quality are unmatched. With SHINE's domestically-produced, high-specificity Lu-177, you have the power to create a brighter future for cancer patients. Ready to transform cancer treatment? Contact us today to discover how SHINE's Lu-177 can help you develop the next generation of targeted therapies. https://hubs.li/Q02D1slG0

Last week, the SHINE team celebrated the filing of our Drug Master File for Ilumira (n.c.a Lu-177) with the FDA, a significant step in bringing this life-saving radioisotope to cancer patients. We had even more to celebrate, too -- over the weekend, we shipped out our largest order of Ilumira to date. Ilumira is a critical radioisotope that can improve the lives of countless cancer patients and their families. These achievements are a testament to our dedicated team's hard work and innovation, who continue to overcome challenges and put patients first. We're proud of the progress we've made in developing a new, faster, and better technology for producing life-saving radioisotopes. This is just the beginning for SHINE, and we're committed to building a brighter future for all. Read the recent press release on our submission: https://hubs.li/Q02DK2nc0

We celebrated a special anniversary this week with University of Wisconsin-Madison on their 175th Anniversary Tour stop in Janesville. Our Founder and CEO, Greg Piefer, pioneered the technology that our facility now uses while getting a PhD from UW-Madison’s nuclear engineering program. We hosted a lunch panel for employees with UW-Alumni Association’s Sarah Schutt and Greg’s former Professor, Paul Wilson, UW Nuclear Engineering and Engineering Physics. We ended the day with a spirited community celebration, with Greg sharing the importance of the local entrepreneurship that attracted him to bring SHINE to Janesville. #UW175

When every minute counts in cancer treatment, reliable access to radioisotopes can make all the difference. At SHINE, we're not just producing Lu-177 – we're delivering hope. Read how our team's decade-long commitment to innovation helped a young patient at Cincinnati Children's Hospital stay on track with their life-saving treatment. From conference booth to hospital delivery in just 72 hours, this is the power of a resilient supply chain in action. Learn more about how we are revolutionizing radioisotope availability and why it matters for patients. https://hubs.li/Q02CV3HW0 #CancerCare #Radioisotopes #HealthcareInnovation #Lu-177 #nuclearmedicine

Fusion is an evolutionary inevitability, and we are accelerating the route to practical fusion energy. Our Founder and CEO, Greg Piefer, recently shared SHINE's vision for achieving fusion energy faster at #Fusion24 in London. We're commercializing the highest-value applications of “fusion first,” such as non-destructive testing and life-saving medical isotope production. Industrializing fusion in this way progressively decreases its cost and carves out a scalable path to practical fusion energy. #fusionenergy #medicalisotopes #NDT

SHINE Technologies and Zeno Power are teaming up to tackle the challenge of nuclear waste by converting it into clean energy. SHINE plans to provide Zeno with Strontium-90 to power Radioisotope Power Systems (RPSs). RPSs are like long-lasting batteries that use the natural decay of radioactive materials to generate electricity. RPSs could be used in space exploration, military equipment, and other applications that require reliable power in remote or harsh environments -- from the depths of the ocean to the surface of the moon! Learn more about this exciting development in our press release. https://hubs.li/Q02CdyFZ0

At the American Nuclear Society Annual Conference on Tuesday, June 18th, Chief Technology Officer Ross Radel will discuss how SHINE is revolutionizing fusion and isotope production to address critical supply challenges and support a sustainable nuclear energy future. As part of the "Our Friends the Isotopes" session, he'll cover 1) Commercializing fusion to provide neutron irradiation services and address isotope shortages 2) Developing a UNF recycling pilot facility 3) Leading a sustainable approach to nuclear energy that tackles waste challenges and provides critical isotopes #ANSannual #AllInOnNuclear

Chief Technology Officer Ross Radel will be speaking next week at ANS. Stay tuned for more information!